Origami Therapeutics

0 reviews

Origami Therapeutics is a preclinical-stage biopharmaceutical company dedicated to developing innovative small-molecule therapies for neurodegenerative diseases. Utilizing their proprietary ORICISION™ drug discovery platform, Origami focuses on creating protein degraders and conformation correctors that target and eliminate disease-causing proteins, aiming to modify disease progression and improve patient outcomes. Key Features and Functionality: - Protein Degradation: Origami's therapies are designed to selectively degrade and remove misfolded or toxic proteins implicated in neurodegenerative diseases, while preserving normal protein function. - Small-Molecule Therapeutics: The company develops orally administrable small molecules, ensuring broad distribution within the body and facilitating ease of manufacturing. - ORICISION™ Platform: This proprietary platform enables the discovery of both protein degraders and conformation correctors, allowing for tailored treatments based on patient-derived disease models. - Targeting "Undruggable" Proteins: Origami's approach addresses proteins traditionally considered "undruggable," expanding therapeutic possibilities for various neurodegenerative conditions. Primary Value and Problem Solved: Origami Therapeutics addresses the critical need for disease-modifying treatments in neurodegenerative disorders by targeting the root cause—misfolded or toxic proteins. Their innovative therapies aim to halt or slow disease progression, offering hope for improved quality of life for patients suffering from conditions like Huntington's disease, Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis (ALS), and frontotemporal dementia.